Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 2Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 2Transfusion Reaction 1Thrombocytopenia 1Multiple Sclerosis 1Motor Activity 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1Hematologic Diseases 1

Interventions

Brentuximab Vedotin 17fludarabine 9Cyclophosphamide 9dacetuzumab 6Lenalidomide 6Bortezomib 6ruxolitinib 5fludarabine phosphate 5Rituximab 5Melphalan 5Dexamethasone 4Busulfan 4lintuzumab 3Whole-Body Irradiation 3Mycophenolic Acid 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Doxorubicin 3Calcium Dobesilate 3Azacitidine 3vosaroxin 2spartalizumab 2ponatinib 2nilotinib 2Vincristine 2Thiotepa 2Tacrolimus 2Sugars 2Stem Cell Transplantation 2Rifampin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Hematologic Diseases × Platelet Transfusion × Clear all
NCT00000589 2016-11-07

Trial to Reduce Alloimmunization to Platelets (TRAP)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 3 Completed
Other hematologic neoplasm

Hematologic Diseases, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡